Email
IZ Express #1,802: Child dies of measles, COVID-19 and influenza vaccine effectiveness, and more
| From | Immunize.org <[email protected]> |
| Subject | IZ Express #1,802: Child dies of measles, COVID-19 and influenza vaccine effectiveness, and more |
| Date | March 5, 2025 11:17 AM |
Links have been removed from this email. Learn more in the FAQ.
Links have been removed from this email. Learn more in the FAQ.
[link removed]
[link removed]
[link removed] [link removed]
Email not displaying correctly? View it in your browser ([link removed]).
[link removed]
Issue 1,802: March 5, 2025
Top Stories
* First U.S. measles death reported since 2015 as outbreaks grow; review and optimize your MMR vaccination practice with resources from Immunize.org
* “Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years—VISION and IVY Networks, September 2024–January 2025” published in MMWR
* “Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness—Four Vaccine Effectiveness Networks, United States, October 2024–February 2025” published in MMWR
* “Reports of Encephalopathy Among Children with Influenza-Associated Mortality—United States, 2010–11 Through 2024–25 Influenza Seasons” published in MMWR
* “Trends in Cervical Precancers Identified Through Population-Based Surveillance—Human Papillomavirus Vaccine Impact Monitoring Project, Five Sites, United States, 2008–2022” published in MMWR
* Immunize.org updates its “Standing Orders for Administering Recombinant Zoster Vaccine (Shingrix) to Adults” template
* Influenza continues to hit hard across the country; vaccination protects
* Journalists interview Immunize.org experts
* Vaccines in the news
Immunize.org Website and Clinical Resources
* Spotlight on the website: CDC Resources
* Recap: Immunize.org updated these clinical resources in January and February
* Recap: Immunize.org reviews, updates “Ask the Experts: Documenting Vaccination,” and adds three new questions
* Recap: Immunize.org reviews, updates “Ask the Experts: Billing & Reimbursement,” and adds a question on Medicaid policies
* Recap: Immunize.org updates two “Questions and Answers” resources, one for Haemophilus influenzae type b (Hib) and one for pneumococcus
Featured Resources
* Updated 65+ Flu Defense website offers resources for healthcare professionals serving older adults
* While supplies last, order laminated 2025 U.S. immunization schedule booklets from Immunize.org
Notable Publications
* Georgetown University publishes "H5N1 Influenza Vaccines and the Current Outbreak"
Upcoming Events
* Virtual: Hepatitis B Foundation and National Viral Hepatitis Roundtable host webinars on preventing liver cancer through vaccination on March 11 at 3:00 p.m. (ET) and March 18 at 3:00 p.m. (ET)
* Questions about our website? Register for Immunize.org Website Office Hours March 12 at 4:00 p.m. (ET) or March 13 at 12:00 p.m. (ET). Previously recorded sessions available online.
------------------------------------------------------------
Top Stories
------------------------------------------------------------
First U.S. measles death reported since 2015 as outbreaks grow; review and optimize your MMR vaccination practice with resources from Immunize.org
In late February, the Texas Department of State Health Services reported the death of an unvaccinated school-aged child at a hospital in Lubbock, the first United States death from measles since 2015. As of February 28, Texas reports 146 measles cases, with 20 hospitalizations, as a part of the growing outbreak that began in Gaines County, Texas, in late January.
Measles was declared eliminated from the United States in 2000, meaning that the virus does not continuously spread in this country, although outbreaks can happen when the virus is introduced through travel. If measles spreads continuously within the United States for more than 1 year, then the United States will lose its status as a country that has eliminated measles.
CDC updates its 2025 count of measles cases in the United States on its Measles Cases and Outbreaks ([link removed]) web page each Friday. From January 1 through February 27, 164 measles cases in nine states were reported to CDC. These states include Alaska, California, Georgia, Kentucky, New Jersey, New Mexico, New York, Rhode Island, and Texas. Healthcare professionals should prepare to recognize and respond to measles in their practice.
MMR vaccine is the best defense against measles infection. One dose administered after the first birthday is 93% effective in preventing measles infection, and a second dose, which may be administered a minimum of one month later, increases effectiveness to 97%. The vaccine can also prevent or reduce the severity of infection if administered to an unvaccinated person up to 3 days after an exposure.
Immunize.org offers useful resources to support vaccination providers who offer MMR vaccine, including a standing orders template and other clinical resources to address the questions or concerns of parents and vaccine recipients. See our Vaccines A–Z: Measles ([link removed]) page to find everything we offer to support measles vaccination.
Related Links
* CDC: Measles Cases and Outbreaks ([link removed]) web page
* CDC: Measles (Rubeola) ([link removed]) web section
* Immunize.org: Vaccines A–Z Measles ([link removed]) main page
* Immunize.org: Standing Orders for Administering Measles, Mumps, and Rubella Vaccine to Children and Teens ([link removed])
* Immunize.org: Standing Orders for Administering Measles, Mumps, and Rubella Vaccine to Adults ([link removed])
* AP News: A Texas Child Who Was Not Vaccinated Has Died of Measles, a First for the U.S. in a Decade ([link removed]) (2/26/25)
------------------------------------------------------------
“Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years—VISION and IVY Networks, September 2024–January 2025” published in MMWR
CDC published Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years—VISION and IVY Networks, September 2024–January 2025 ([link removed]) on February 27 in MMWR. A portion of the summary appears below.
Vaccine effectiveness (VE) of 2024–2025 COVID-19 vaccine was 33% against COVID-19–associated emergency department (ED) or urgent care (UC) visits among adults aged ≥18 years and 45%–46% against hospitalizations among immunocompetent adults aged ≥65 years, compared with not receiving a 2024–2025 vaccine dose. VE against hospitalizations in immunocompromised adults aged ≥65 years was 40%. . . .
These findings indicate that 2024–2025 COVID-19 vaccination provides additional protection against COVID-19–associated ED/UC encounters and hospitalization, versus no 2024–2025 vaccination and support CDC and ACIP recommendations that all persons aged ≥6 months receive 2024–2025 COVID-19 vaccination.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]) .
Related Link
* CDC: MMWR main page ([link removed]) providing access to the MMWR family of publications
------------------------------------------------------------
“Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness—Four Vaccine Effectiveness Networks, United States, October 2024–February 2025” published in MMWR
CDC published Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness—Four Vaccine Effectiveness Networks, United States, October 2024–February 2025 ([link removed]) on February 27 in MMWR. A portion of the discussion appears below.
These interim estimates of 2024–25 VE indicate that influenza vaccination was effective in preventing medically attended influenza-associated illness in children, adolescents, and adults in the United States. Among children and adolescents, VE against medically attended influenza ranged from 32% to 60% in outpatient settings and from 63% to 78% against influenza-associated hospitalization. Among adults, VE against medically attended influenza was 36% and 54% in two outpatient settings and 41% and 55% against influenza-associated hospitalization. Despite increased circulation of influenza A(H3N2) viruses, which are generally associated with lower VE (3), estimates from this influenza season were consistent with those from the 2023–24 season and seasons associated with higher VE over the last 15 years.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Link
* CDC: MMWR main page ([link removed]) providing access to the MMWR family of publications
------------------------------------------------------------
“Reports of Encephalopathy Among Children with Influenza-Associated Mortality—United States, 2010–11 Through 2024–25 Influenza Seasons” published in MMWR
CDC published Reports of Encephalopathy Among Children with Influenza-Associated Mortality—United States, 2010–11 Through 2024–25 Influenza Seasons ([link removed]) on February 27 in MMWR. A portion of the summary appears below.
Influenza-associated encephalopathy or encephalitis (IAE), including acute necrotizing encephalopathy (ANE), is a rare and potentially fatal complication of influenza. No national IAE surveillance exists. . . .
During late January 2025, CDC received anecdotal reports of critically ill children with IAE, including deaths with ANE. Data from the Influenza-Associated Pediatric Mortality Surveillance System was investigated and revealed the median proportion of pediatric influenza deaths with IAE during the 2010–11 through 2024–25 influenza seasons was 9%. IAE was identified in 13% (nine of 68) of deaths during the 2024–25 influenza season (through February 8, 2025), including four with ANE. . . .
It is not known whether cases observed in the 2024–25 season vary from expected numbers. Clinicians should consider IAE in children with influenza and abnormal neurologic signs or symptoms. Influenza vaccination is recommended for all persons aged ≥6 months while influenza viruses are circulating.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]) .
Related Link
* CDC: MMWR main page ([link removed]) providing access to the MMWR family of publications
------------------------------------------------------------
“Trends in Cervical Precancers Identified Through Population-Based Surveillance—Human Papillomavirus Vaccine Impact Monitoring Project, Five Sites, United States, 2008–2022” published in MMWR
CDC published Trends in Cervical Precancers Identified Through Population-Based Surveillance—Human Papillomavirus Vaccine Impact Monitoring Project, Five Sites, United States, 2008–2022 ([link removed]) on February 27 in MMWR. A portion of the summary appears below.
Since 2006, when human papillomavirus (HPV) vaccine was first recommended in the United States to prevent cancers and other diseases caused by HPV, vaccination coverage has increased, and many young women vaccinated as children or adolescents have become age-eligible for cervical cancer screening. CDC monitors cervical precancer incidence through the Human Papillomavirus Vaccine Impact Monitoring Project. . . .
During 2008–2022, cervical precancer incidence decreased 79% and higher-grade precancer incidence decreased 80% among screened women aged 20–24 years, the age group most likely to have been vaccinated. . . .
Observed declines in cervical precancers are consistent with HPV vaccination impact and support Advisory Committee on Immunization Practices recommendations to vaccinate children against HPV at age 11–12 years with catch-up through age 26 years.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Link
* CDC: MMWR main page ([link removed]) providing access to the MMWR family of publications
------------------------------------------------------------
Immunize.org updates its “Standing Orders for Administering Recombinant Zoster Vaccine (Shingrix) to Adults” template
Immunize.org updated its Standing Orders for Administering Recombinant Zoster Vaccine (Shingrix) to Adults ([link removed]) template to update URLs and formatting.
Related Links
* Immunize.org: Clinical Resources: Standing Orders Templates ([link removed]) main page
* Immunize.org: Clinical Resources: Zoster (Shingles) ([link removed]) main page
* Immunize.org: Clinical Resources A–Z ([link removed]) main page, where you can filter by topic, vaccine, language, or other criteria
------------------------------------------------------------
Influenza continues to hit hard across the country; vaccination protects
For week 8, ending February 22, CDC’s Weekly U.S. Influenza Surveillance Report, FluView ([link removed]), showed influenza-like illness activity at high to very high levels in 41 of 49 reporting jurisdictions. CDC classified this season as a high-severity season for people of all ages. During week 8, 5.8% of outpatient visits were for influenza-like illness, well above the epidemic threshold of 3.0% for the twelfth consecutive week. Twelve influenza-associated pediatric deaths were reported during week 8, bringing the 2024–25 season total to 98 pediatric deaths.
RESP-NET
Visit the CDC Respiratory Virus Hospitalization Surveillance Network (RESP-NET) ([link removed]) for weekly reports of hospitalizations due to three vaccine-preventable seasonal respiratory viruses: COVID-19, influenza, and RSV. COVID-19 vaccination is recommended for everyone age 6 months and older; RSV vaccination at this point in the season is recommended for certain high-risk adults age 60 through 74 and all adults age 75 years and older. RSV immunization of infants and certain high-risk toddlers with nirsevimab (Beyfortus, Sanofi) is recommended until the end of March.
Influenza Vaccination Dashboard
CDC's Weekly Flu Vaccination Dashboard ([link removed]) shows the latest statistics. Coverage level estimates through February 15 appear below.
* For children age 6 months–17 years, 45.8% of children received a flu vaccination, lower than last season at this time point (50.9%).
* For adults age 18 years and older, 45.3% of adults received a flu vaccination, consistent with last season at this time point.
CDC recommends everyone age 6 months and older get annual influenza vaccination. Given the high levels of circulating influenza across the country, vaccination remains important for all eligible, unvaccinated people.
Identify pharmacies in your area that may offer influenza and COVID-19 vaccines by entering a zip code in the VaccineFinder on Vaccines.gov ([link removed]) or Vacunas.gov ([link removed]).
Related Links
* CDC: Weekly National Flu Vaccination Dashboard ([link removed]) main page
* CDC: FluView ([link removed]) main page
* CDC: RESP-NET ([link removed]) main page
* Immunize.org: free clinical resources and patient handouts related to influenza ([link removed])
* Immunize.org: Vaccines A–Z: Influenza ([link removed]) main page
------------------------------------------------------------
Journalists interview Immunize.org experts
Journalists seek out Immunize.org experts to help explain vaccines to the public and policy makers. We help the media understand and communicate the complex work vaccinators do. Here is a selection of our recent citations.
* CNN: Disrupted U.S. Vaccine Meetings Could Threaten Timelines, Access and Transparency Around Shots ([link removed]) (2/28/25)
* NBC News: Could Flu Shot Supply Fall Short This Year? FDA’s Canceled Meeting Sparks Worries ([link removed]) (2/27/25)
------------------------------------------------------------
Vaccines in the news
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* Washington Post: Rise of Pediatric Flu Cases Is Sending More Children to the Hospital ([link removed]) (3/1/25)
* Fox 7 Austin: Measles in Texas: Austin Doctor Speaks on Recent Virus Outbreak ([link removed]) (2/28/25)
* New York Times: FDA Cancels Meeting of Vaccine Experts Scheduled to Advise on Flu Shots ([link removed]) (2/26/25)
------------------------------------------------------------
Immunize.org Website and Clinical Resources
------------------------------------------------------------
Spotlight on the website: CDC Resources
This week’s spotlight features CDC recommendations and resources. These are accessed by selecting the “Official Guidance” menu, then “CDC” among the lefthand choices, then one of the three righthand choices. This area of our website includes:
* The CDC Recommended Schedules ([link removed]) page features official recommended immunization schedules for children, teens, and adults. You can view or download PDF versions of the schedules, or link to download a schedule app for mobile devices.
* The ACIP Vaccine Recommendations ([link removed]) page provides a list of current and archived ACIP recommendations. Separate tabs display general (not vaccine-specific) or vaccine-specific recommendations. You may filter results to display only current recommendations and you may sort by date. Immunize.org maintains its own collection of PDF copies of ACIP recommendations as published in the MMWR to ensure your uninterrupted access. We also link to CDC’s online MMWR collection.
* The Additional CDC Resources ([link removed]) page offers links to important CDC web pages related to immunization services and public health. You will find links to CDC publications, educational content, reference materials, and contact information.
“Additional CDC Resources” can also be accessed from their respective Vaccines A–Z ([link removed]) pages. View the right menu on those pages and click on “ACIP Vaccine Recommendations” or “CDC Recommended Schedules” to jump directly to their location.
------------------------------------------------------------
Recap: Immunize.org updated these clinical resources in January and February
IZ Express regularly provides readers with information about Immunize.org’s new and updated educational materials for healthcare professionals and handouts for patients. All Immunize.org materials are free to distribute.
In case you missed them during recent weeks, updates were made to these helpful materials:
Immunize.org Updated Materials for Clinicians
* Healthcare Personnel Vaccination Recommendations ([link removed])
* Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools ([link removed])
* Leading Medical Organizations Endorse Strong School and Childcare Vaccine Requirements and Elimination of Non-Medical Exemptions ([link removed])
Materials supporting vaccine administration:
* Hepatitis B vaccination resources
+ Standing Orders for Administering Hepatitis B Vaccine Children and Teens ([link removed])
+ Standing Orders for Administering Hepatitis B Vaccine to Adults ([link removed])
+ Hepatitis A and Hepatitis B Vaccines: Be Sure Your Patients Get the Correct Dose ([link removed])
+ Hepatitis B and Healthcare Personnel ([link removed])
* Before You Vaccinate Adults, Consider Their “H-A-L-O”! ([link removed])
* Vaccine Administration Record for children and teens ([link removed]) ; and for adults ([link removed])
* Quick Chart of Vaccine-Preventable Disease Terms in Multiple Languages ([link removed])
* Notification of Immunization Letter Template ([link removed])
* Temperature logs, storage and handling resources:
+ Temperature Logs for Refrigerator Celsius ([link removed]) and Fahrenheit ([link removed])
+ Temperature Logs for Freezer Celsius ([link removed]) and Fahrenheit ([link removed])
+ Checklist for Safe Vaccine Storage and Handling ([link removed])
+ Vaccine Storage Emergency Response Worksheet ([link removed])
+ Don't Be Guilty of These Preventable Errors in Vaccine Storage and Handling! ([link removed])
+ Supplies You May Need at an Immunization Clinic ([link removed])
Immunize.org Updated Printable Materials for Your Patients
* Haemophilus Influenzae Type B (Hib): Questions and Answers ([link removed])
* Hepatitis B: Questions and Answers ([link removed])
* Pneumococcus: Questions and Answers ([link removed])
* Evidence Shows Vaccines Unrelated to Autism ([link removed])
Immunize.org Web Pages
* Ask the Experts Vaccine Topics: Hib (Haemophilus influenzae type b) ([link removed]), Hepatitis B ([link removed]), and Dengue ([link removed])
* Ask the Experts General Topics: Billing & Reimbursement ([link removed]), Documenting Vaccination ([link removed]), and Vaccine Recommendations ([link removed])
* Vaccine Confidence & Addressing Concerns: Complementary and Alternative Medicine: Partner Resources ([link removed])
* New! Image Library: Mpox Images ([link removed])
Archived Immunize.org Website Office Hours Webinars
* New! Website Office Hours: Official Guidance, Part 1 (CDC, FDA, WHO) ([link removed])
* New! Website Office Hours: Official Guidance, Part 2 (State Resources) ([link removed])
------------------------------------------------------------
Recap: Immunize.org reviews, updates “Ask the Experts: Documenting Vaccination,” and adds three new questions
Immunize.org reviewed the content of its Ask the Experts: Documenting Vaccination ([link removed]) web page, updating answers, including hyperlinks to CDC references that changed during CDC’s recent website restructuring program. Three new questions and answers were added:
* What is the Countermeasures Injury Compensation Program (CICP)?
* Does providing a digital copy of a VIS count, or must we give a paper VIS?
* What is a vaccine EUA fact sheet and when do I use one?
------------------------------------------------------------
Recap: Immunize.org reviews, updates “Ask the Experts: Billing & Reimbursement,” and adds a question on Medicaid policies
Immunize.org reviewed and updated the content of its Ask the Experts: Billing & Reimbursement ([link removed]) web page, updating answers, including CDC website links. The answers reflect current Medicare and Medicaid payment policies.
New questions and answers were added: What vaccines are covered by Medicaid? Does coverage vary by state?
------------------------------------------------------------
Recap: Immunize.org updates two “Questions and Answers” resources, one for Haemophilus influenzae type b (Hib) and one for pneumococcus
Immunize.org updated two of its "Questions and Answers" resources.
* Haemophilus influenzae type b (Hib): Questions and Answers ([link removed]): Edits update morbidity data and expand information on Hib vaccine safety
* Pneumococcus: Questions and Answers ([link removed]): Edits incorporate PCV21 (Capvaxive, Merck) recommendations and describe CDC's PneumoRecs VaxAdvisor app as a valuable tool to determine pneumococcal vaccine needs based on a person's age, health condition, and vaccination history
------------------------------------------------------------
Featured Resources
------------------------------------------------------------
Updated 65+ Flu Defense website offers resources for healthcare professionals serving older adults
Confident healthcare provider recommendations for influenza vaccine are powerfully persuasive. This influenza season has been a tough one, and it is far from over. To help you maximize patient protection, Immunize.org, in collaboration with CSL Seqirus, updated the 65+ Flu Defense ([link removed]) website.
This helpful site includes information, tools, and tips for communicating with adults age 65 and older about the scope and severity of influenza. Resources include:
* Influenza in Adults 65+: The Facts ([link removed])
* Influenza Vaccination: Questions Patients Aged 65 and Older Frequently Ask Their HCP ([link removed])
* The Importance of Preventing Influenza and COVID-19 ([link removed])
Older adults are at increased risk of severe influenza, COVID-19, and RSV illness, including hospitalization and death, especially if they are not up to date on these vaccinations. A clinician recommendation is the most important reason why a patient will get vaccinated.
Check out the updated 65+ Flu Defense ([link removed]) website to assist your ongoing efforts in protecting this vulnerable population.
------------------------------------------------------------
While supplies last, order laminated 2025 U.S. immunization schedule booklets from Immunize.org
Laminated booklets of the 2025 U.S. child and adolescent immunization schedule ([link removed]) and the 2025 U.S. adult immunization schedule ([link removed]) are available now in the Immunize.org shop.
The schedules are available online as PDFs from CDC ([link removed]) at no cost. Immunize.org’s laminated booklets are ideal for use in any busy healthcare setting where vaccines are given. Features include:
* Durability: Their tough coating can be wiped down, and they can stand up to a year's worth of use.
* Format: Each schedule is produced in an 8.5” X 11” booklet format; with color coding for easy reading, our laminated schedules replicate the original CDC formatting, including all tables and notes. The adult schedule is 16 pages and the child and adolescent schedule is 20 pages.
* Easy access to CDC updates: The CDC online schedule includes an addendum page that will display ACIP’s new recommendations as CDC adopts them during 2025. Each Immunize.org laminated schedule addendum page includes QR codes you can scan to view or print the online addendum page as it is revised.
* Bonus content: Both schedules include a bonus page with Immunize.org’s popular 1-page handout summarizing the dose, route, and needle size recommendations for all vaccines and recipients.
Pricing:
Child and Adolescent Booklets Adult Booklets
1 copy: $10.50 1 copy: $10.00
2–4 copies: $10.00 each 2–4 copies: $9.50 each
5–19 copies: $9.00 each 5–19 copies: $8.50 each
20–99 copies: $8.00 each 20–99 copies: $7.50 each
100–499 copies: $6.50 each 100–499 copies: $6.00 each
500–999 copies: $5.50 each 500–999 copies: $5.00 each
1,000–1,999 copies: $4.50 each 1,000–1,999 copies: $4.00 each
2,000+ copies: $3.75 each 2,000+ copies: $3.25 each
Visit the Shop Immunize.org: Laminated Schedules ([link removed]) web page to view images and order today!
For additional information, call 651-647-9009 or email [email protected].
Related Links
* Immunize.org: Laminated Child and Adolescent Immunization Schedules (0–18 years) ([link removed]) web page
* Immunize.org: Laminated Adult Immunization Schedules (19 and older) ([link removed]) web page
* Immunize.org: Shop Immunize.org ([link removed]) main page
------------------------------------------------------------
Notable Publications
------------------------------------------------------------
Georgetown University publishes "H5N1 Influenza Vaccines and the Current Outbreak"
Georgetown University's Global Health Institute published H5N1 Influenza Vaccines and the Current Outbreak ([link removed]). Immunize.org’s Dr. Kelly Moore served on the panel that contributed to the meeting and paper. Key points from the summary appear below.
The current H5N1 influenza outbreak represents a challenge to global health security. On November 15, 2024, Georgetown University convened a webinar bringing together 20 experts from epidemiology, virology, vaccine development, regulatory science, and public health, engaging with an online audience of over 200 participants. . . .
This document summarizes gaps identified and recommends specific actions to undertake now to help address them. In addition, three overarching major priorities were identified that demand immediate attention.
* Resource and implement a Manhattan Project/Operation Warp Speed type initiative . . . to develop and assess . . . H5 and other pandemic influenza vaccines . . .
* Develop and implement comprehensive strategies to rebuild trust in and ensure effective delivery of critical public health messages. . . .
* H5 pandemic playbooks should be made public, and outgoing and incoming administrations should act together to exercise and test plans at the national, regional and local levels.
[link removed]
------------------------------------------------------------
Upcoming Events
------------------------------------------------------------
Virtual: Hepatitis B Foundation and National Viral Hepatitis Roundtable host webinars on preventing liver cancer through vaccination on March 11 at 3:00 p.m. (ET) and March 18 at 3:00 p.m. (ET)
Hepatitis B Foundation, in partnership with the National Viral Hepatitis Roundtable, will host a webinar titled Preventing Liver Cancer From Birth with the Hepatitis B Vaccine ([link removed]), 3:00–4:00 p.m. (ET) on March 11 and 3:00–4:00 p.m. (ET) on March 18.
During this 2-part webinar, panelists will discuss how to prevent liver cancer through vaccination. In part one, panelists will discuss the importance of the HepB birth dose, and the burden of hepatitis B before the routine infant recommendation. In part two, panelists will discuss how to speak about vaccines in the current landscape.
Register for the webinar ([link removed]).
------------------------------------------------------------
Questions about our website? Register for Immunize.org Website Office Hours March 12 at 4:00 p.m. (ET) or March 13 at 12:00 p.m. (ET). Previously recorded sessions available online.
To learn simple tips and tricks for using our website efficiently, please register for our next set of Website Office Hours on Wednesday, March 12 at 4:00 p.m. (ET) ([link removed]) or Thursday, March 13 at 12:00 p.m. (ET) ([link removed]). The same content will be covered in both sessions.
We will open each 45-minute session with a short, live demonstration on navigating the following site content: images, webinars, videos, and social media. You can submit questions when you register or live on Zoom during the session.
Register today for Immunize.org Website Office Hours (content is the same for both):
* Wednesday, March 12 at 4:00 p.m. (ET) ([link removed])
* Thursday, March 13 at 12:00 p.m. (ET) ([link removed])
The archive of previous Website Office Hours content is posted at Immunize.org’s Webinars & Videos ([link removed]) page.
Mark your calendar ([link removed]) for future Immunize.org Website Office Hours.
------------------------------------------------------------
For more upcoming events, visit our Calendar of Events ([link removed]).
Editorial Information
Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Grabenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Kayla Ohlde
About IZ Express
Immunize.org welcomes redistribution of this issue of IZ Express or selected articles.
When you do so, please add a note that Immunize.org is the source of the material and provide a link to this issue ([link removed]).
IZ Express is supported in part by Grant No. NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer (http:// [link removed])
ISSN: 2771-8085
To unsubscribe to this publication, go to: [link removed]
==============================================
Unsubscribe [email protected] from this list:
[link removed]
[link removed]
[link removed] [link removed]
Email not displaying correctly? View it in your browser ([link removed]).
[link removed]
Issue 1,802: March 5, 2025
Top Stories
* First U.S. measles death reported since 2015 as outbreaks grow; review and optimize your MMR vaccination practice with resources from Immunize.org
* “Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years—VISION and IVY Networks, September 2024–January 2025” published in MMWR
* “Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness—Four Vaccine Effectiveness Networks, United States, October 2024–February 2025” published in MMWR
* “Reports of Encephalopathy Among Children with Influenza-Associated Mortality—United States, 2010–11 Through 2024–25 Influenza Seasons” published in MMWR
* “Trends in Cervical Precancers Identified Through Population-Based Surveillance—Human Papillomavirus Vaccine Impact Monitoring Project, Five Sites, United States, 2008–2022” published in MMWR
* Immunize.org updates its “Standing Orders for Administering Recombinant Zoster Vaccine (Shingrix) to Adults” template
* Influenza continues to hit hard across the country; vaccination protects
* Journalists interview Immunize.org experts
* Vaccines in the news
Immunize.org Website and Clinical Resources
* Spotlight on the website: CDC Resources
* Recap: Immunize.org updated these clinical resources in January and February
* Recap: Immunize.org reviews, updates “Ask the Experts: Documenting Vaccination,” and adds three new questions
* Recap: Immunize.org reviews, updates “Ask the Experts: Billing & Reimbursement,” and adds a question on Medicaid policies
* Recap: Immunize.org updates two “Questions and Answers” resources, one for Haemophilus influenzae type b (Hib) and one for pneumococcus
Featured Resources
* Updated 65+ Flu Defense website offers resources for healthcare professionals serving older adults
* While supplies last, order laminated 2025 U.S. immunization schedule booklets from Immunize.org
Notable Publications
* Georgetown University publishes "H5N1 Influenza Vaccines and the Current Outbreak"
Upcoming Events
* Virtual: Hepatitis B Foundation and National Viral Hepatitis Roundtable host webinars on preventing liver cancer through vaccination on March 11 at 3:00 p.m. (ET) and March 18 at 3:00 p.m. (ET)
* Questions about our website? Register for Immunize.org Website Office Hours March 12 at 4:00 p.m. (ET) or March 13 at 12:00 p.m. (ET). Previously recorded sessions available online.
------------------------------------------------------------
Top Stories
------------------------------------------------------------
First U.S. measles death reported since 2015 as outbreaks grow; review and optimize your MMR vaccination practice with resources from Immunize.org
In late February, the Texas Department of State Health Services reported the death of an unvaccinated school-aged child at a hospital in Lubbock, the first United States death from measles since 2015. As of February 28, Texas reports 146 measles cases, with 20 hospitalizations, as a part of the growing outbreak that began in Gaines County, Texas, in late January.
Measles was declared eliminated from the United States in 2000, meaning that the virus does not continuously spread in this country, although outbreaks can happen when the virus is introduced through travel. If measles spreads continuously within the United States for more than 1 year, then the United States will lose its status as a country that has eliminated measles.
CDC updates its 2025 count of measles cases in the United States on its Measles Cases and Outbreaks ([link removed]) web page each Friday. From January 1 through February 27, 164 measles cases in nine states were reported to CDC. These states include Alaska, California, Georgia, Kentucky, New Jersey, New Mexico, New York, Rhode Island, and Texas. Healthcare professionals should prepare to recognize and respond to measles in their practice.
MMR vaccine is the best defense against measles infection. One dose administered after the first birthday is 93% effective in preventing measles infection, and a second dose, which may be administered a minimum of one month later, increases effectiveness to 97%. The vaccine can also prevent or reduce the severity of infection if administered to an unvaccinated person up to 3 days after an exposure.
Immunize.org offers useful resources to support vaccination providers who offer MMR vaccine, including a standing orders template and other clinical resources to address the questions or concerns of parents and vaccine recipients. See our Vaccines A–Z: Measles ([link removed]) page to find everything we offer to support measles vaccination.
Related Links
* CDC: Measles Cases and Outbreaks ([link removed]) web page
* CDC: Measles (Rubeola) ([link removed]) web section
* Immunize.org: Vaccines A–Z Measles ([link removed]) main page
* Immunize.org: Standing Orders for Administering Measles, Mumps, and Rubella Vaccine to Children and Teens ([link removed])
* Immunize.org: Standing Orders for Administering Measles, Mumps, and Rubella Vaccine to Adults ([link removed])
* AP News: A Texas Child Who Was Not Vaccinated Has Died of Measles, a First for the U.S. in a Decade ([link removed]) (2/26/25)
------------------------------------------------------------
“Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years—VISION and IVY Networks, September 2024–January 2025” published in MMWR
CDC published Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years—VISION and IVY Networks, September 2024–January 2025 ([link removed]) on February 27 in MMWR. A portion of the summary appears below.
Vaccine effectiveness (VE) of 2024–2025 COVID-19 vaccine was 33% against COVID-19–associated emergency department (ED) or urgent care (UC) visits among adults aged ≥18 years and 45%–46% against hospitalizations among immunocompetent adults aged ≥65 years, compared with not receiving a 2024–2025 vaccine dose. VE against hospitalizations in immunocompromised adults aged ≥65 years was 40%. . . .
These findings indicate that 2024–2025 COVID-19 vaccination provides additional protection against COVID-19–associated ED/UC encounters and hospitalization, versus no 2024–2025 vaccination and support CDC and ACIP recommendations that all persons aged ≥6 months receive 2024–2025 COVID-19 vaccination.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]) .
Related Link
* CDC: MMWR main page ([link removed]) providing access to the MMWR family of publications
------------------------------------------------------------
“Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness—Four Vaccine Effectiveness Networks, United States, October 2024–February 2025” published in MMWR
CDC published Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness—Four Vaccine Effectiveness Networks, United States, October 2024–February 2025 ([link removed]) on February 27 in MMWR. A portion of the discussion appears below.
These interim estimates of 2024–25 VE indicate that influenza vaccination was effective in preventing medically attended influenza-associated illness in children, adolescents, and adults in the United States. Among children and adolescents, VE against medically attended influenza ranged from 32% to 60% in outpatient settings and from 63% to 78% against influenza-associated hospitalization. Among adults, VE against medically attended influenza was 36% and 54% in two outpatient settings and 41% and 55% against influenza-associated hospitalization. Despite increased circulation of influenza A(H3N2) viruses, which are generally associated with lower VE (3), estimates from this influenza season were consistent with those from the 2023–24 season and seasons associated with higher VE over the last 15 years.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Link
* CDC: MMWR main page ([link removed]) providing access to the MMWR family of publications
------------------------------------------------------------
“Reports of Encephalopathy Among Children with Influenza-Associated Mortality—United States, 2010–11 Through 2024–25 Influenza Seasons” published in MMWR
CDC published Reports of Encephalopathy Among Children with Influenza-Associated Mortality—United States, 2010–11 Through 2024–25 Influenza Seasons ([link removed]) on February 27 in MMWR. A portion of the summary appears below.
Influenza-associated encephalopathy or encephalitis (IAE), including acute necrotizing encephalopathy (ANE), is a rare and potentially fatal complication of influenza. No national IAE surveillance exists. . . .
During late January 2025, CDC received anecdotal reports of critically ill children with IAE, including deaths with ANE. Data from the Influenza-Associated Pediatric Mortality Surveillance System was investigated and revealed the median proportion of pediatric influenza deaths with IAE during the 2010–11 through 2024–25 influenza seasons was 9%. IAE was identified in 13% (nine of 68) of deaths during the 2024–25 influenza season (through February 8, 2025), including four with ANE. . . .
It is not known whether cases observed in the 2024–25 season vary from expected numbers. Clinicians should consider IAE in children with influenza and abnormal neurologic signs or symptoms. Influenza vaccination is recommended for all persons aged ≥6 months while influenza viruses are circulating.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]) .
Related Link
* CDC: MMWR main page ([link removed]) providing access to the MMWR family of publications
------------------------------------------------------------
“Trends in Cervical Precancers Identified Through Population-Based Surveillance—Human Papillomavirus Vaccine Impact Monitoring Project, Five Sites, United States, 2008–2022” published in MMWR
CDC published Trends in Cervical Precancers Identified Through Population-Based Surveillance—Human Papillomavirus Vaccine Impact Monitoring Project, Five Sites, United States, 2008–2022 ([link removed]) on February 27 in MMWR. A portion of the summary appears below.
Since 2006, when human papillomavirus (HPV) vaccine was first recommended in the United States to prevent cancers and other diseases caused by HPV, vaccination coverage has increased, and many young women vaccinated as children or adolescents have become age-eligible for cervical cancer screening. CDC monitors cervical precancer incidence through the Human Papillomavirus Vaccine Impact Monitoring Project. . . .
During 2008–2022, cervical precancer incidence decreased 79% and higher-grade precancer incidence decreased 80% among screened women aged 20–24 years, the age group most likely to have been vaccinated. . . .
Observed declines in cervical precancers are consistent with HPV vaccination impact and support Advisory Committee on Immunization Practices recommendations to vaccinate children against HPV at age 11–12 years with catch-up through age 26 years.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Link
* CDC: MMWR main page ([link removed]) providing access to the MMWR family of publications
------------------------------------------------------------
Immunize.org updates its “Standing Orders for Administering Recombinant Zoster Vaccine (Shingrix) to Adults” template
Immunize.org updated its Standing Orders for Administering Recombinant Zoster Vaccine (Shingrix) to Adults ([link removed]) template to update URLs and formatting.
Related Links
* Immunize.org: Clinical Resources: Standing Orders Templates ([link removed]) main page
* Immunize.org: Clinical Resources: Zoster (Shingles) ([link removed]) main page
* Immunize.org: Clinical Resources A–Z ([link removed]) main page, where you can filter by topic, vaccine, language, or other criteria
------------------------------------------------------------
Influenza continues to hit hard across the country; vaccination protects
For week 8, ending February 22, CDC’s Weekly U.S. Influenza Surveillance Report, FluView ([link removed]), showed influenza-like illness activity at high to very high levels in 41 of 49 reporting jurisdictions. CDC classified this season as a high-severity season for people of all ages. During week 8, 5.8% of outpatient visits were for influenza-like illness, well above the epidemic threshold of 3.0% for the twelfth consecutive week. Twelve influenza-associated pediatric deaths were reported during week 8, bringing the 2024–25 season total to 98 pediatric deaths.
RESP-NET
Visit the CDC Respiratory Virus Hospitalization Surveillance Network (RESP-NET) ([link removed]) for weekly reports of hospitalizations due to three vaccine-preventable seasonal respiratory viruses: COVID-19, influenza, and RSV. COVID-19 vaccination is recommended for everyone age 6 months and older; RSV vaccination at this point in the season is recommended for certain high-risk adults age 60 through 74 and all adults age 75 years and older. RSV immunization of infants and certain high-risk toddlers with nirsevimab (Beyfortus, Sanofi) is recommended until the end of March.
Influenza Vaccination Dashboard
CDC's Weekly Flu Vaccination Dashboard ([link removed]) shows the latest statistics. Coverage level estimates through February 15 appear below.
* For children age 6 months–17 years, 45.8% of children received a flu vaccination, lower than last season at this time point (50.9%).
* For adults age 18 years and older, 45.3% of adults received a flu vaccination, consistent with last season at this time point.
CDC recommends everyone age 6 months and older get annual influenza vaccination. Given the high levels of circulating influenza across the country, vaccination remains important for all eligible, unvaccinated people.
Identify pharmacies in your area that may offer influenza and COVID-19 vaccines by entering a zip code in the VaccineFinder on Vaccines.gov ([link removed]) or Vacunas.gov ([link removed]).
Related Links
* CDC: Weekly National Flu Vaccination Dashboard ([link removed]) main page
* CDC: FluView ([link removed]) main page
* CDC: RESP-NET ([link removed]) main page
* Immunize.org: free clinical resources and patient handouts related to influenza ([link removed])
* Immunize.org: Vaccines A–Z: Influenza ([link removed]) main page
------------------------------------------------------------
Journalists interview Immunize.org experts
Journalists seek out Immunize.org experts to help explain vaccines to the public and policy makers. We help the media understand and communicate the complex work vaccinators do. Here is a selection of our recent citations.
* CNN: Disrupted U.S. Vaccine Meetings Could Threaten Timelines, Access and Transparency Around Shots ([link removed]) (2/28/25)
* NBC News: Could Flu Shot Supply Fall Short This Year? FDA’s Canceled Meeting Sparks Worries ([link removed]) (2/27/25)
------------------------------------------------------------
Vaccines in the news
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* Washington Post: Rise of Pediatric Flu Cases Is Sending More Children to the Hospital ([link removed]) (3/1/25)
* Fox 7 Austin: Measles in Texas: Austin Doctor Speaks on Recent Virus Outbreak ([link removed]) (2/28/25)
* New York Times: FDA Cancels Meeting of Vaccine Experts Scheduled to Advise on Flu Shots ([link removed]) (2/26/25)
------------------------------------------------------------
Immunize.org Website and Clinical Resources
------------------------------------------------------------
Spotlight on the website: CDC Resources
This week’s spotlight features CDC recommendations and resources. These are accessed by selecting the “Official Guidance” menu, then “CDC” among the lefthand choices, then one of the three righthand choices. This area of our website includes:
* The CDC Recommended Schedules ([link removed]) page features official recommended immunization schedules for children, teens, and adults. You can view or download PDF versions of the schedules, or link to download a schedule app for mobile devices.
* The ACIP Vaccine Recommendations ([link removed]) page provides a list of current and archived ACIP recommendations. Separate tabs display general (not vaccine-specific) or vaccine-specific recommendations. You may filter results to display only current recommendations and you may sort by date. Immunize.org maintains its own collection of PDF copies of ACIP recommendations as published in the MMWR to ensure your uninterrupted access. We also link to CDC’s online MMWR collection.
* The Additional CDC Resources ([link removed]) page offers links to important CDC web pages related to immunization services and public health. You will find links to CDC publications, educational content, reference materials, and contact information.
“Additional CDC Resources” can also be accessed from their respective Vaccines A–Z ([link removed]) pages. View the right menu on those pages and click on “ACIP Vaccine Recommendations” or “CDC Recommended Schedules” to jump directly to their location.
------------------------------------------------------------
Recap: Immunize.org updated these clinical resources in January and February
IZ Express regularly provides readers with information about Immunize.org’s new and updated educational materials for healthcare professionals and handouts for patients. All Immunize.org materials are free to distribute.
In case you missed them during recent weeks, updates were made to these helpful materials:
Immunize.org Updated Materials for Clinicians
* Healthcare Personnel Vaccination Recommendations ([link removed])
* Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools ([link removed])
* Leading Medical Organizations Endorse Strong School and Childcare Vaccine Requirements and Elimination of Non-Medical Exemptions ([link removed])
Materials supporting vaccine administration:
* Hepatitis B vaccination resources
+ Standing Orders for Administering Hepatitis B Vaccine Children and Teens ([link removed])
+ Standing Orders for Administering Hepatitis B Vaccine to Adults ([link removed])
+ Hepatitis A and Hepatitis B Vaccines: Be Sure Your Patients Get the Correct Dose ([link removed])
+ Hepatitis B and Healthcare Personnel ([link removed])
* Before You Vaccinate Adults, Consider Their “H-A-L-O”! ([link removed])
* Vaccine Administration Record for children and teens ([link removed]) ; and for adults ([link removed])
* Quick Chart of Vaccine-Preventable Disease Terms in Multiple Languages ([link removed])
* Notification of Immunization Letter Template ([link removed])
* Temperature logs, storage and handling resources:
+ Temperature Logs for Refrigerator Celsius ([link removed]) and Fahrenheit ([link removed])
+ Temperature Logs for Freezer Celsius ([link removed]) and Fahrenheit ([link removed])
+ Checklist for Safe Vaccine Storage and Handling ([link removed])
+ Vaccine Storage Emergency Response Worksheet ([link removed])
+ Don't Be Guilty of These Preventable Errors in Vaccine Storage and Handling! ([link removed])
+ Supplies You May Need at an Immunization Clinic ([link removed])
Immunize.org Updated Printable Materials for Your Patients
* Haemophilus Influenzae Type B (Hib): Questions and Answers ([link removed])
* Hepatitis B: Questions and Answers ([link removed])
* Pneumococcus: Questions and Answers ([link removed])
* Evidence Shows Vaccines Unrelated to Autism ([link removed])
Immunize.org Web Pages
* Ask the Experts Vaccine Topics: Hib (Haemophilus influenzae type b) ([link removed]), Hepatitis B ([link removed]), and Dengue ([link removed])
* Ask the Experts General Topics: Billing & Reimbursement ([link removed]), Documenting Vaccination ([link removed]), and Vaccine Recommendations ([link removed])
* Vaccine Confidence & Addressing Concerns: Complementary and Alternative Medicine: Partner Resources ([link removed])
* New! Image Library: Mpox Images ([link removed])
Archived Immunize.org Website Office Hours Webinars
* New! Website Office Hours: Official Guidance, Part 1 (CDC, FDA, WHO) ([link removed])
* New! Website Office Hours: Official Guidance, Part 2 (State Resources) ([link removed])
------------------------------------------------------------
Recap: Immunize.org reviews, updates “Ask the Experts: Documenting Vaccination,” and adds three new questions
Immunize.org reviewed the content of its Ask the Experts: Documenting Vaccination ([link removed]) web page, updating answers, including hyperlinks to CDC references that changed during CDC’s recent website restructuring program. Three new questions and answers were added:
* What is the Countermeasures Injury Compensation Program (CICP)?
* Does providing a digital copy of a VIS count, or must we give a paper VIS?
* What is a vaccine EUA fact sheet and when do I use one?
------------------------------------------------------------
Recap: Immunize.org reviews, updates “Ask the Experts: Billing & Reimbursement,” and adds a question on Medicaid policies
Immunize.org reviewed and updated the content of its Ask the Experts: Billing & Reimbursement ([link removed]) web page, updating answers, including CDC website links. The answers reflect current Medicare and Medicaid payment policies.
New questions and answers were added: What vaccines are covered by Medicaid? Does coverage vary by state?
------------------------------------------------------------
Recap: Immunize.org updates two “Questions and Answers” resources, one for Haemophilus influenzae type b (Hib) and one for pneumococcus
Immunize.org updated two of its "Questions and Answers" resources.
* Haemophilus influenzae type b (Hib): Questions and Answers ([link removed]): Edits update morbidity data and expand information on Hib vaccine safety
* Pneumococcus: Questions and Answers ([link removed]): Edits incorporate PCV21 (Capvaxive, Merck) recommendations and describe CDC's PneumoRecs VaxAdvisor app as a valuable tool to determine pneumococcal vaccine needs based on a person's age, health condition, and vaccination history
------------------------------------------------------------
Featured Resources
------------------------------------------------------------
Updated 65+ Flu Defense website offers resources for healthcare professionals serving older adults
Confident healthcare provider recommendations for influenza vaccine are powerfully persuasive. This influenza season has been a tough one, and it is far from over. To help you maximize patient protection, Immunize.org, in collaboration with CSL Seqirus, updated the 65+ Flu Defense ([link removed]) website.
This helpful site includes information, tools, and tips for communicating with adults age 65 and older about the scope and severity of influenza. Resources include:
* Influenza in Adults 65+: The Facts ([link removed])
* Influenza Vaccination: Questions Patients Aged 65 and Older Frequently Ask Their HCP ([link removed])
* The Importance of Preventing Influenza and COVID-19 ([link removed])
Older adults are at increased risk of severe influenza, COVID-19, and RSV illness, including hospitalization and death, especially if they are not up to date on these vaccinations. A clinician recommendation is the most important reason why a patient will get vaccinated.
Check out the updated 65+ Flu Defense ([link removed]) website to assist your ongoing efforts in protecting this vulnerable population.
------------------------------------------------------------
While supplies last, order laminated 2025 U.S. immunization schedule booklets from Immunize.org
Laminated booklets of the 2025 U.S. child and adolescent immunization schedule ([link removed]) and the 2025 U.S. adult immunization schedule ([link removed]) are available now in the Immunize.org shop.
The schedules are available online as PDFs from CDC ([link removed]) at no cost. Immunize.org’s laminated booklets are ideal for use in any busy healthcare setting where vaccines are given. Features include:
* Durability: Their tough coating can be wiped down, and they can stand up to a year's worth of use.
* Format: Each schedule is produced in an 8.5” X 11” booklet format; with color coding for easy reading, our laminated schedules replicate the original CDC formatting, including all tables and notes. The adult schedule is 16 pages and the child and adolescent schedule is 20 pages.
* Easy access to CDC updates: The CDC online schedule includes an addendum page that will display ACIP’s new recommendations as CDC adopts them during 2025. Each Immunize.org laminated schedule addendum page includes QR codes you can scan to view or print the online addendum page as it is revised.
* Bonus content: Both schedules include a bonus page with Immunize.org’s popular 1-page handout summarizing the dose, route, and needle size recommendations for all vaccines and recipients.
Pricing:
Child and Adolescent Booklets Adult Booklets
1 copy: $10.50 1 copy: $10.00
2–4 copies: $10.00 each 2–4 copies: $9.50 each
5–19 copies: $9.00 each 5–19 copies: $8.50 each
20–99 copies: $8.00 each 20–99 copies: $7.50 each
100–499 copies: $6.50 each 100–499 copies: $6.00 each
500–999 copies: $5.50 each 500–999 copies: $5.00 each
1,000–1,999 copies: $4.50 each 1,000–1,999 copies: $4.00 each
2,000+ copies: $3.75 each 2,000+ copies: $3.25 each
Visit the Shop Immunize.org: Laminated Schedules ([link removed]) web page to view images and order today!
For additional information, call 651-647-9009 or email [email protected].
Related Links
* Immunize.org: Laminated Child and Adolescent Immunization Schedules (0–18 years) ([link removed]) web page
* Immunize.org: Laminated Adult Immunization Schedules (19 and older) ([link removed]) web page
* Immunize.org: Shop Immunize.org ([link removed]) main page
------------------------------------------------------------
Notable Publications
------------------------------------------------------------
Georgetown University publishes "H5N1 Influenza Vaccines and the Current Outbreak"
Georgetown University's Global Health Institute published H5N1 Influenza Vaccines and the Current Outbreak ([link removed]). Immunize.org’s Dr. Kelly Moore served on the panel that contributed to the meeting and paper. Key points from the summary appear below.
The current H5N1 influenza outbreak represents a challenge to global health security. On November 15, 2024, Georgetown University convened a webinar bringing together 20 experts from epidemiology, virology, vaccine development, regulatory science, and public health, engaging with an online audience of over 200 participants. . . .
This document summarizes gaps identified and recommends specific actions to undertake now to help address them. In addition, three overarching major priorities were identified that demand immediate attention.
* Resource and implement a Manhattan Project/Operation Warp Speed type initiative . . . to develop and assess . . . H5 and other pandemic influenza vaccines . . .
* Develop and implement comprehensive strategies to rebuild trust in and ensure effective delivery of critical public health messages. . . .
* H5 pandemic playbooks should be made public, and outgoing and incoming administrations should act together to exercise and test plans at the national, regional and local levels.
[link removed]
------------------------------------------------------------
Upcoming Events
------------------------------------------------------------
Virtual: Hepatitis B Foundation and National Viral Hepatitis Roundtable host webinars on preventing liver cancer through vaccination on March 11 at 3:00 p.m. (ET) and March 18 at 3:00 p.m. (ET)
Hepatitis B Foundation, in partnership with the National Viral Hepatitis Roundtable, will host a webinar titled Preventing Liver Cancer From Birth with the Hepatitis B Vaccine ([link removed]), 3:00–4:00 p.m. (ET) on March 11 and 3:00–4:00 p.m. (ET) on March 18.
During this 2-part webinar, panelists will discuss how to prevent liver cancer through vaccination. In part one, panelists will discuss the importance of the HepB birth dose, and the burden of hepatitis B before the routine infant recommendation. In part two, panelists will discuss how to speak about vaccines in the current landscape.
Register for the webinar ([link removed]).
------------------------------------------------------------
Questions about our website? Register for Immunize.org Website Office Hours March 12 at 4:00 p.m. (ET) or March 13 at 12:00 p.m. (ET). Previously recorded sessions available online.
To learn simple tips and tricks for using our website efficiently, please register for our next set of Website Office Hours on Wednesday, March 12 at 4:00 p.m. (ET) ([link removed]) or Thursday, March 13 at 12:00 p.m. (ET) ([link removed]). The same content will be covered in both sessions.
We will open each 45-minute session with a short, live demonstration on navigating the following site content: images, webinars, videos, and social media. You can submit questions when you register or live on Zoom during the session.
Register today for Immunize.org Website Office Hours (content is the same for both):
* Wednesday, March 12 at 4:00 p.m. (ET) ([link removed])
* Thursday, March 13 at 12:00 p.m. (ET) ([link removed])
The archive of previous Website Office Hours content is posted at Immunize.org’s Webinars & Videos ([link removed]) page.
Mark your calendar ([link removed]) for future Immunize.org Website Office Hours.
------------------------------------------------------------
For more upcoming events, visit our Calendar of Events ([link removed]).
Editorial Information
Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Grabenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Kayla Ohlde
About IZ Express
Immunize.org welcomes redistribution of this issue of IZ Express or selected articles.
When you do so, please add a note that Immunize.org is the source of the material and provide a link to this issue ([link removed]).
IZ Express is supported in part by Grant No. NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer (http:// [link removed])
ISSN: 2771-8085
To unsubscribe to this publication, go to: [link removed]
==============================================
Unsubscribe [email protected] from this list:
[link removed]
Message Analysis
- Sender: Immunization Action Coalition
- Political Party: n/a
- Country: United States
- State/Locality: n/a
- Office: n/a
-
Email Providers:
- MailChimp